Literature DB >> 35707145

Novel Bis-phosphoglycerate Mutase Modulators for Treating Sickle Cell Disease.

Ram W Sabnis1.   

Abstract

Entities:  

Year:  2022        PMID： 35707145      PMCID： PMC9190288          DOI： 10.1021/acsmedchemlett.2c00181

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN： 1948-5875            Impact factor:   4.632


× No keyword cloud information.
  6 in total

Review 1.  Complement in sickle cell disease and targeted therapy: I know one thing, that I know nothing.

Authors:  Athina Tampaki; Eleni Gavriilaki; Christos Varelas; Achilles Anagnostopoulos; Efthymia Vlachaki
Journal:  Blood Rev       Date:  2021-01-21       Impact factor: 8.250

2.  A systematic review of quality of life in sickle cell disease and thalassemia after stem cell transplant or gene therapy.

Authors:  Sherif M Badawy; Usman Beg; Robert I Liem; Sonali Chaudhury; Alexis A Thompson
Journal:  Blood Adv       Date:  2021-01-26

Review 3.  l-glutamine, crizanlizumab, voxelotor, and cell-based therapy for adult sickle cell disease: Hype or hope?

Authors:  Jennifer N Leibovitch; Ajay V Tambe; Emanuela Cimpeanu; Maria Poplawska; Firas Jafri; Dibyendu Dutta; Seah H Lim
Journal:  Blood Rev       Date:  2022-01-01       Impact factor: 8.250

Review 4.  Burden of central nervous system complications in sickle cell disease: A systematic review and meta-analysis.

Authors:  Soyon Lee; Sedge Lucas; David Proudman; Dave Nellesen; Jincy Paulose; Vivien A Sheehan
Journal:  Pediatr Blood Cancer       Date:  2022-01-17       Impact factor: 3.838

Review 5.  Gene therapy for sickle cell disease: moving from the bench to the bedside.

Authors:  Allistair A Abraham; John F Tisdale
Journal:  Blood       Date:  2021-09-16       Impact factor: 25.476

Review 6.  Impact of hemoglobin biophysical studies on molecular pathogenesis and drug therapy for sickle cell disease.

Authors:  William A Eaton
Journal:  Mol Aspects Med       Date:  2021-07-14
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.